Nuvalent, Inc.
General ticker "NUVL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.1B (TTM average)
Nuvalent, Inc. follows the US Stock Market performance with the rate: 45.6%.
Estimated limits based on current volatility of 0.1%: low 123.94$, high 124.04$
Factors to consider:
- Total employees count: 142 (+54.3%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Product development failure, Regulatory and compliance, Capital shortage, Commercialization challenges
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [67.29$, 137.63$]
- 2026-12-31 to 2027-12-31 estimated range: [49.26$, 107.32$]
Financial Metrics affecting the NUVL estimates:
- Negative: with PPE of -18.8 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 88.37 > 64.23
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
Short-term NUVL quotes
Long-term NUVL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $149.49MM | $280.37MM | $414.31MM |
| Operating Income | $-149.49MM | $-280.37MM | $-414.31MM |
| Non-Operating Income | $23.27MM | $20.38MM | $-10.48MM |
| R&D Expense | $113.24MM | $217.77MM | $306.97MM |
| Income(Loss) | $-126.22MM | $-259.99MM | $-424.79MM |
| Taxes | $0.00MM | $0.76MM | $0.58MM |
| Net Income(Loss)* | $-126.22MM | $-260.76MM | $-425.38MM |
| Stockholders Equity | $700.56MM | $1,069.79MM | $1,248.34MM |
| Assets | $732.38MM | $1,141.75MM | $1,412.70MM |
| Operating Cash Flow | $-99.74MM | $-185.06MM | $-275.21MM |
| Investing Cash Flow | $-143.53MM | $-573.51MM | $-124.08MM |
| Financing Cash Flow | $336.85MM | $568.88MM | $515.34MM |
| Earnings Per Share** | $-2.17 | $-3.93 | $-5.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.